Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P41235

UPID:
HNF4A_HUMAN

ALTERNATIVE NAMES:
Nuclear receptor subfamily 2 group A member 1; Transcription factor 14; Transcription factor HNF-4

ALTERNATIVE UPACC:
P41235; A5JW41; B2RPP8; O00659; O00723; Q14540; Q5QPB8; Q6B4V5; Q6B4V6; Q6B4V7; Q92653; Q92654; Q92655; Q99864; Q9NQH0

BACKGROUND:
The protein Hepatocyte nuclear factor 4-alpha, also known as Transcription factor 14 and HNF-4, plays a critical role in liver development and metabolism. It controls the transcription of genes essential for hepatic progenitor cell differentiation and maintains circadian rhythm in liver and colon cells by regulating CLOCK-BMAL1 transcriptional activity.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in diseases like Maturity-onset diabetes of the young 1 and Type 2 diabetes mellitus, understanding the role of Hepatocyte nuclear factor 4-alpha could open doors to potential therapeutic strategies. Its genetic variants are linked to metabolic disorders, highlighting its significance in developing targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.